What is claimed is:

1. A solid oral dosage form comprising a therapeutically effective amount of aliskiren, or a pharmaceutically acceptable salt thereof, wherein the active ingredient is present in an amount of more than 46% by weight based on the total weight of the oral dosage form.

2. A solid oral dosage form according to Claim 1, wherein the active ingredient is present in an amount of more than 48% by weight.

3. A solid oral dosage form according to Claim 1, wherein the active ingredient is present in an amount ranging from 46 to 60% by weight.

4. A solid oral dosage form according to Claim 3, wherein the active ingredient consists entirely of aliskiren, or a pharmaceutically acceptable salt thereof, and is present in an amount ranging from about 75 to about 600 mg of the free base per unit dosage form.

5. A solid oral dosage form according to Claim 4, wherein the active ingredient consists entirely of aliskiren, or a pharmaceutically acceptable salt thereof, and is present in an amount ranging from about 75 to about 300 mg of the free base per unit dosage form.

6. A solid oral dosage form according to Claim 5, wherein aliskiren is in the form of a hemi-fumarate thereof, and is present in an amount of about 83, about 166 or about 332 mg per unit dosage form.

7. A solid oral dosage form according to Claim 6, wherein the dosage form further comprises a filler.

8. A solid oral dosage form according to Claim 7, wherein the filler is microcrystalline cellulose.

9. A solid oral dosage form according to Claim 7, wherein the dosage form further comprises a disintegrant.

10. A solid oral dosage form according to Claim 9, wherein the dosage form further comprises a lubricant.

11. A solid oral dosage form according to Claim 10, wherein the dosage form further comprises a glidant.

12. A solid oral dosage form according to Claim 11, wherein the dosage form further comprises a binder.

13. A solid oral dosage form according to Claim 12 for the treatment of hypertension, congestive heart failure, angina, myocardial infarction, artherosclerosis, diabetic nephropathy, diabetic cardiac myopathy, renal insufficiency, peripheral vascular disease, left ventricular hypertrophy, cognitive dysfunction, stroke, headache and chronic heart failure.

14. A solid oral dosage form according to Claim 1 for the treatment of hypertension, congestive heart failure, angina, myocardial infarction, artherosclerosis, diabetic nephropathy, diabetic cardiac myopathy, renal insufficiency, peripheral vascular disease, left ventricular hypertrophy, cognitive dysfunction, stroke, headache and chronic heart failure.

15. A method for the treatment of hypertension, congestive heart failure, angina, myocardial infarction, artherosclerosis, diabetic nephropathy, diabetic cardiac myopathy, renal insufficiency, peripheral vascular disease, left ventricular hypertrophy, cognitive dysfunction, stroke, headache and chronic heart failure which method comprises administering a therapeutically effective amount of a solid oral dosage form according to Claim 1 to a patient in need thereof.

16. A method for the treatment of hypertension, congestive heart failure, angina, myocardial infarction, artherosclerosis, diabetic nephropathy, diabetic cardiac myopathy, renal insufficiency, peripheral vascular disease, left ventricular hypertrophy, cognitive dysfunction, stroke, headache and chronic heart failure which method comprises administering a therapeutically effective amount of a solid oral dosage form according to Claim 12 to a patient in need thereof.

17. Use of a solid oral dosage form according Claim 1 for the manufacture of a medicament for the treatment of hypertension, congestive heart failure, angina, myocardial infarction, artherosclerosis, diabetic nephropathy, diabetic cardiac myopathy, renal insufficiency, peripheral vascular disease, left ventricular hypertrophy, cognitive dysfunction, stroke, headache and chronic heart failure.

18. Use of a solid oral dosage form according Claim 12 for the manufacture of a medicament for the treatment of hypertension, congestive heart failure, angina, myocardial infarction, artherosclerosis, diabetic nephropathy, diabetic cardiac myopathy, renal

insufficiency, peripheral vascular disease, left ventricular hypertrophy, cognitive dysfunction, stroke, headache and chronic heart failure.

19. A process for the manufacture of a solid oral dosage form according to Claim 12 comprising:

1) mixing the active ingredient and additives and granulating said components with a granulation liquid;
2) drying a resulting granulate;
3) mixing the dried granulate with outer phase excipients;
4) compressing a resulting mixture to form a solid oral dosage as a core tablet; and
5) optionally coating a resulting core tablet to give a film-coated tablet.

20. A process according to Claim 19, wherein the additives in step (1) are selected from a filler, a disintegrant and a binder; and the outer phase excipients in step (3) are selected from a filler, a disintegrant, a lubricant and a glidant.